Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update
10 août 2021 16h05 HE
|
Clearside Biomedical, Inc.
- Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021 – - Upcoming FDA PDUFA Action Date in October 2021 for XIPERE™ (triamcinolone acetonide...
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021
04 août 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021
27 juil. 2021 16h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 27, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
15 juin 2021 07h05 HE
|
Clearside Biomedical, Inc.
- CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events - - Initiating Cohort 2 patient screening for 0.1 mg dose in June 2021 - ...
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021
09 juin 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update
17 mai 2021 16h05 HE
|
Clearside Biomedical, Inc.
- Recent New Drug Application Resubmission for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) - - Cohort 1 Data in OASIS Wet AMD Phase 1/2a Trial Expected in...
Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
10 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021
04 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
03 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit
05 avr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...